Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib with Adjuvant CAPEOX in Operable Colorectal Cancer
NCT03228043Withdrawn
- Sponsor
- Nanchong City Central Hospital
- Start
- Mar 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of Rivoceranib in colorectal cancer (CRC) (2 arms), sponsored by Nanchong City Central Hospital. Primary endpoints: Recurrence-free survival at 1 year and Overall survival at 1 year. Planned start Mar 2020; status: withdrawn.
02
Drugs
Rivoceranib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03228043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03228043.